KUALA LUMPUR, Feb 3 -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions has launched a new B2m-NOG mouse model, expanding its premier immuno-oncology portfolio.
The portfolio is built on the CIEA NOG mouse®, a severely immunodeficient mouse with diverse applications based on its improved ability to engraft human cells and tissues.
According to a statement, B2m-NOG significantly extends the study window after human peripheral blood mononuclear (PBMC) cell engraftment, providing more time to assess reactions to target drugs.
The extended study window dramatically expands immuno-oncology study types that can be run using the B2m-NOG model compared with more expensive and time-consuming options, such as hematopoietic stem cell-engrafted models.
Taconic also offers B2m-NOG mice pre-engrafted with human PBMCs.
Immuno-oncology leverages the body’s immune system to fight cancer, increasing the ability to target the disease.
Animal models used in this therapeutic development include special mice, which model human immune system function.
-- BERNAMA
Wednesday, 5 February 2020
Solid Sphere Inc distributes Takeshobo Quest - POP TEAM EPIC ASSAULTS overseas
KUALA LUMPUR, Feb 3 -- Solid Sphere Inc, a game content developer for various platforms has begun distribution of an overseas version of the ‘Takeshobo Quest - POP TEAM EPIC ASSAULTS’ smartphone app.
According to a statement, Takeshobo Quest - POP TEAM EPIC ASSAULTS is an original kuso app based on the world view of Bkub Okawa's popular POP TEAM EPIC manga.
Supported by both iOS and Android devices, player attempts to clear stages by collecting Takeshobo employees and defeating Popuko and Pipimi.
Providing basic play for free, the app is available in countries namely, China (including Hong Kong and Macau), Taiwan, Korea, Singapore, Thailand, Vietnam, Malaysia and Indonesia.
More details at https://www.pptp.jp.
-- BERNAMA
Willis Lease Finance Corporation, key industry partners launch MRO Blockchain Alliance
KUALA LUMPUR, Feb 5 -- Willis Lease Finance Corporation and key industry partners have launched the MRO Blockchain Alliance, the air transport sector’s first industry-wide investigation into the use of blockchain to trace, track and record aircraft parts.
The new alliance is made up of leading organisations covering every aspect of the commercial aviation maintenance, repair and overhaul (MRO) chain, from parts manufacturing and repairs to logistics and smart contracts.
The alliance members so far, include Bolloré Logistics, Cathay Pacific, FLYdocs, HAECO Group, Ramco Systems, SAFRAN, SITA and Willis Lease Finance Corporation, all supported by Clyde & Co.
In the coming months, the alliance will launch a proof of concept to explore how they can use blockchain to digitally track and record the movement and maintenance history of parts across a wide number of players, including airlines, lessors and original equipment manufacturers.
The MRO Blockchain Alliance believes that the use of blockchain will simplify and speed up the process of tracking parts and securely sharing information across the industry, according to a statement.
In addition, PwC estimates that the use of blockchain could increase aerospace industry revenues by as much as four per cent or US$40 billion, while cutting MRO costs globally by around five per cent or US$3.5 billion. (US$1 = RM4.12)
The alliance will spend the next six months in a continued planning phase, with the aim of going live with the first proof of concept in the third quarter this year.
In the coming months, the alliance will launch a proof of concept to explore how they can use blockchain to digitally track and record the movement and maintenance history of parts across a wide number of players, including airlines, lessors and original equipment manufacturers.
The MRO Blockchain Alliance believes that the use of blockchain will simplify and speed up the process of tracking parts and securely sharing information across the industry, according to a statement.
In addition, PwC estimates that the use of blockchain could increase aerospace industry revenues by as much as four per cent or US$40 billion, while cutting MRO costs globally by around five per cent or US$3.5 billion. (US$1 = RM4.12)
The alliance will spend the next six months in a continued planning phase, with the aim of going live with the first proof of concept in the third quarter this year.
-- BERNAMA
Teledyne Princeton Instruments expands NIRvana SWIR camera portfolio
KUALA LUMPUR, Feb 5 -- Teledyne Princeton Instruments, part of the Teledyne Imaging group has announced the immediate availability of its newest offering in the NIRvana® SWIR portfolio, NIRvana HS.
The NIRvana HS offers an exciting, truly innovative set of world-class performance features utilising the advantages of the second near-infrared window (NIR-II) to meet the increasingly diverse needs of today’s scientific, industrial and medical communities.
Building on the success of the high performance NIRvana LN (liquid nitrogen cooled) and the NIRvana 640 (super-cooled), the NIRvana HS version combines speed, flexibility, performance and value, bringing new capability to science and industry.
The HS runs at an amazing 250 frames per second in 16 bit mode and offers both integrate-then-read and integrate-while-read modes for low noise and high duty cycle, according to a statement.
The advanced thermal design includes deep cooling to -55C and incorporates the most advanced vacuum sealed chamber to provide a lifetime of maintenance free operation. Advanced image correction ensures the camera delivers unmatched image quality.
The NIRvana family of products has led to advances in many applications including astronomy, life sciences and semiconductor fabrication.
More details at https://www.princetoninstruments.com.
-- BERNAMA
The NIRvana HS offers an exciting, truly innovative set of world-class performance features utilising the advantages of the second near-infrared window (NIR-II) to meet the increasingly diverse needs of today’s scientific, industrial and medical communities.
Building on the success of the high performance NIRvana LN (liquid nitrogen cooled) and the NIRvana 640 (super-cooled), the NIRvana HS version combines speed, flexibility, performance and value, bringing new capability to science and industry.
The HS runs at an amazing 250 frames per second in 16 bit mode and offers both integrate-then-read and integrate-while-read modes for low noise and high duty cycle, according to a statement.
The advanced thermal design includes deep cooling to -55C and incorporates the most advanced vacuum sealed chamber to provide a lifetime of maintenance free operation. Advanced image correction ensures the camera delivers unmatched image quality.
The NIRvana family of products has led to advances in many applications including astronomy, life sciences and semiconductor fabrication.
More details at https://www.princetoninstruments.com.
-- BERNAMA
Tuesday, 4 February 2020
BEST'S MARKET SEGMENT REPORT: THAILAND NON-LIFE INSURANCE SEGMENT REMAINS ROBUST DESPITE NARROWING PROFIT MARGINS
SINGAPORE, Feb 4 (Bernama-BUSINESS WIRE) -- AM Best expects motor, health and personal accident (PA), as well as property lines businesses to remain growth drivers for Thailand’s non-life market, although profitability may face rising pressure given the fierce market competition and the need for insurers to improve pricing and operational sophistication.
A new Best’s Market Segment Report, titled, “Thailand Non-Life Insurance Segment Remains Robust Despite Narrowing Profit Margins,” states that in 2018, the Thailand non-life insurance segment posted THB 232 billion (USD 7.5 billion) in direct premium written (DPW), making it the second-largest non-life insurance market in Southeast Asia. AM Best considers the market’s earnings to be adequate; however, various segments of the market are facing difficulties in maintaining underwriting margins. Between 2015 and 2018, the market’s combined ratio rose moderately, to 97% from 92%, while its return on equity weakened to 5% from 11%.
As the largest line of business, motor insurance will continue to dominate Thailand’s non-life insurance segment and will remain a key driver of overall market growth. According to the Office of Insurance Commission (OIC), in the first nine months of 2019, motor premiums grew by 5.4% and were a significant driver of the non-life segment’s overall expansion of 4.7%. However, recent statistics from the OIC show a deterioration in motor insurance underwriting results, which declined to an estimated loss (based on AM Best’s calculation) of THB 1.6 billion in 2018 from a technical profit of THB 2.6 billion in 2013.
Although the health and PA business in Thailand’s non-life segment remains profitable, the segment’s profit margins also have come under increasing pressure. In 2018, the market posted an underwriting profit of THB 1.4 billion, compared with THB 1.9 billion in 2013, while the combined ratio increased moderately during this timeframe, to 95%, from 90%, due mainly to a higher loss ratio.
Although the property insurance line of business (fire and industrial all risks) constitutes just 15% of DPW, it contributes more than 50% of the industry’s underwriting profit. However, despite its profitability, the segment’s loss ratio has been rising and premium volume declining. The market turned positive recently, with property DPW increasing by 2.3% during the first nine months of 2019. AM Best expects growth in this segment to increase given the likelihood of increased government spending on transportation and energy projects, along with foreign investment in the economic development of Thailand’s eastern seaboard.
Overall, despite some concerns about the lackluster underwriting results of Thailand’s non-life insurance industry, AM Best views the market’s balance sheet as strong. The non-life insurance segment has maintained a reasonably solid track record of solvency in recent years, and the industry’s capital adequacy ratio remains well-above minimum regulatory requirements.
To access the full copy of this market segment report please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=293973.
AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in New York, London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.
Copyright © 2020 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20200203005461/en/
Contact
Tran Nhat Trung
Financial Analyst
+65 6303 5019
trung.tran@ambest.com
Doniella Pliss
Director, Analytics
+65 6303 5024
doniella.pliss@ambest.com
Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com
Jim Peavy
Director, Public Relations
+1 908 439 2200, ext. 5644
james.peavy@ambest.com
Source : AM Best
A new Best’s Market Segment Report, titled, “Thailand Non-Life Insurance Segment Remains Robust Despite Narrowing Profit Margins,” states that in 2018, the Thailand non-life insurance segment posted THB 232 billion (USD 7.5 billion) in direct premium written (DPW), making it the second-largest non-life insurance market in Southeast Asia. AM Best considers the market’s earnings to be adequate; however, various segments of the market are facing difficulties in maintaining underwriting margins. Between 2015 and 2018, the market’s combined ratio rose moderately, to 97% from 92%, while its return on equity weakened to 5% from 11%.
As the largest line of business, motor insurance will continue to dominate Thailand’s non-life insurance segment and will remain a key driver of overall market growth. According to the Office of Insurance Commission (OIC), in the first nine months of 2019, motor premiums grew by 5.4% and were a significant driver of the non-life segment’s overall expansion of 4.7%. However, recent statistics from the OIC show a deterioration in motor insurance underwriting results, which declined to an estimated loss (based on AM Best’s calculation) of THB 1.6 billion in 2018 from a technical profit of THB 2.6 billion in 2013.
Although the health and PA business in Thailand’s non-life segment remains profitable, the segment’s profit margins also have come under increasing pressure. In 2018, the market posted an underwriting profit of THB 1.4 billion, compared with THB 1.9 billion in 2013, while the combined ratio increased moderately during this timeframe, to 95%, from 90%, due mainly to a higher loss ratio.
Although the property insurance line of business (fire and industrial all risks) constitutes just 15% of DPW, it contributes more than 50% of the industry’s underwriting profit. However, despite its profitability, the segment’s loss ratio has been rising and premium volume declining. The market turned positive recently, with property DPW increasing by 2.3% during the first nine months of 2019. AM Best expects growth in this segment to increase given the likelihood of increased government spending on transportation and energy projects, along with foreign investment in the economic development of Thailand’s eastern seaboard.
Overall, despite some concerns about the lackluster underwriting results of Thailand’s non-life insurance industry, AM Best views the market’s balance sheet as strong. The non-life insurance segment has maintained a reasonably solid track record of solvency in recent years, and the industry’s capital adequacy ratio remains well-above minimum regulatory requirements.
To access the full copy of this market segment report please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=293973.
AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in New York, London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.
Copyright © 2020 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20200203005461/en/
Contact
Tran Nhat Trung
Financial Analyst
+65 6303 5019
trung.tran@ambest.com
Doniella Pliss
Director, Analytics
+65 6303 5024
doniella.pliss@ambest.com
Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com
Jim Peavy
Director, Public Relations
+1 908 439 2200, ext. 5644
james.peavy@ambest.com
Source : AM Best
Monday, 3 February 2020
David Hope is ForgeRock Asia-Pacific, Japan SVP
KUALA LUMPUR, Jan 29 -- ForgeRock®, the leading provider in digital identity has appointed David Hope as senior vice-president (SVP) for Asia-Pacific and Japan.
His appointment signifies ForgeRock’s growing investment in Asia-Pacific and underscores its aim to serve as the digital identity partner of choice for large enterprise organisations in the region.
“David is an exceptional operator known for growing businesses in the Asia-Pacific region. He will be a great addition to our team and will help further strengthen our position as a leading digital identity provider for Fortune 5000 customers,” said ForgeRock chief revenue officer, Pete Angstadt.
Hope will play an instrumental role in expanding ForgeRock’s presence across Asia-Pacific, focusing on business development, channel expansion and growing the regional team.
“I am excited and honoured to join Pete and the team. ForgeRock has an exciting customer base, and is uniquely positioned to serve the digital identity needs of the enterprise with its comprehensive platform that is cloud-ready and its commitment to customer success is second to none,” said Hope.
He joins ForgeRock with over 20 years of experience in enterprise IT leadership roles. Previously, Hope was the president of Asia-Pacific at Workday where he led the rapid expansion of the business across the region.
More details at www.forgerock.com.
-- BERNAMA
His appointment signifies ForgeRock’s growing investment in Asia-Pacific and underscores its aim to serve as the digital identity partner of choice for large enterprise organisations in the region.
“David is an exceptional operator known for growing businesses in the Asia-Pacific region. He will be a great addition to our team and will help further strengthen our position as a leading digital identity provider for Fortune 5000 customers,” said ForgeRock chief revenue officer, Pete Angstadt.
Hope will play an instrumental role in expanding ForgeRock’s presence across Asia-Pacific, focusing on business development, channel expansion and growing the regional team.
“I am excited and honoured to join Pete and the team. ForgeRock has an exciting customer base, and is uniquely positioned to serve the digital identity needs of the enterprise with its comprehensive platform that is cloud-ready and its commitment to customer success is second to none,” said Hope.
He joins ForgeRock with over 20 years of experience in enterprise IT leadership roles. Previously, Hope was the president of Asia-Pacific at Workday where he led the rapid expansion of the business across the region.
More details at www.forgerock.com.
-- BERNAMA
CENTRIENT PHARMACEUTICALS APPOINTS REX CLEMENTS AS CHIEF EXECUTIVE OFFICER AFTER KARL ROTTHIER DECIDES TO STEP DOWN FROM THE ROLE
ROTTERDAM, The Netherlands, Jan 30 (Bernama-GLOBE NEWSWIRE) -- Centrient Pharmaceuticals, the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins and anti-fungals, is announcing that Karl Rotthier has decided to step down as CEO after having built a highly successful company over the last ten years and managing a smooth transition to the new ownership under Bain Capital.
Karl has successfully led the company for almost for 10 years, bringing Centrient to a unique position within the industry. Karl should be extremely proud for achieving these results. As Centrient is now well positioned on its growth trajectory for another potential record year in 2020, Karl decided that now is the best time to take a step back and let Centrient Pharmaceuticals be led by a new CEO who will bring fresh perspectives for the next phase of growth.
The Supervisory Board of Directors hereby announces the appointment of Rex Clements as new CEO, effective as of March 16, 2020. Rex Clements will have the mandate to drive and execute the strategy defined by the Supervisory Board of Directors and the Executive Committee, pursuing the growth trajectory the company has already set in motion.
Rex Clements is a recognised, well-rounded leader, with a proven track record in the pharmaceutical industry. He brings more than 20 years of rich experience gained across multiple assignments in the industry.
Karl Rotthier: “It has been an extremely fulfilling experience to lead the Centrient Pharmaceuticals team to success over the last 10 years; culminating with Centrient becoming a true leader in our industry. Our Mission, Vision and Value Proposition make Centrient Pharmaceuticals unique in the market. I am proud and confident that the company is well positioned to keep growing over the coming years both organically and inorganically. The quality of our people and leadership will continue to make the difference in our highly competitive environment.”
Ben Kunstler, Managing Director at Bain Capital Private Equity and Chairman of the Supervisory Board of Directors at Centrient Pharmaceuticals: “I want to thank Karl for his great leadership, professionalism and work ethic over the years. This was a decision Karl made over the last few months after careful consideration. The appointment of Rex Clements, a respected professional with substantial industry knowledge, as the CEO of Centrient Pharmaceuticals, will allow us to bring the company to an even greater level of performance through the focused pursuit of our growth ambitions. We are looking forward to actively work with Rex and set Centrient Pharmaceuticals on the path to long term, sustainable success.”
Rex Clements: “I am honored to join such a great company like Centrient Pharmaceuticals and to build on the success achieved by Karl. I look forward to working with the Centrient Supervisory Board of Directors, the Executive Committee and all of the employees of Centrient to keep raising the bar of the performance of the company and for our customers and patients.”
http://mrem.bernama.com/viewsm.php?idm=36647
Karl has successfully led the company for almost for 10 years, bringing Centrient to a unique position within the industry. Karl should be extremely proud for achieving these results. As Centrient is now well positioned on its growth trajectory for another potential record year in 2020, Karl decided that now is the best time to take a step back and let Centrient Pharmaceuticals be led by a new CEO who will bring fresh perspectives for the next phase of growth.
The Supervisory Board of Directors hereby announces the appointment of Rex Clements as new CEO, effective as of March 16, 2020. Rex Clements will have the mandate to drive and execute the strategy defined by the Supervisory Board of Directors and the Executive Committee, pursuing the growth trajectory the company has already set in motion.
Rex Clements is a recognised, well-rounded leader, with a proven track record in the pharmaceutical industry. He brings more than 20 years of rich experience gained across multiple assignments in the industry.
Karl Rotthier: “It has been an extremely fulfilling experience to lead the Centrient Pharmaceuticals team to success over the last 10 years; culminating with Centrient becoming a true leader in our industry. Our Mission, Vision and Value Proposition make Centrient Pharmaceuticals unique in the market. I am proud and confident that the company is well positioned to keep growing over the coming years both organically and inorganically. The quality of our people and leadership will continue to make the difference in our highly competitive environment.”
Ben Kunstler, Managing Director at Bain Capital Private Equity and Chairman of the Supervisory Board of Directors at Centrient Pharmaceuticals: “I want to thank Karl for his great leadership, professionalism and work ethic over the years. This was a decision Karl made over the last few months after careful consideration. The appointment of Rex Clements, a respected professional with substantial industry knowledge, as the CEO of Centrient Pharmaceuticals, will allow us to bring the company to an even greater level of performance through the focused pursuit of our growth ambitions. We are looking forward to actively work with Rex and set Centrient Pharmaceuticals on the path to long term, sustainable success.”
Rex Clements: “I am honored to join such a great company like Centrient Pharmaceuticals and to build on the success achieved by Karl. I look forward to working with the Centrient Supervisory Board of Directors, the Executive Committee and all of the employees of Centrient to keep raising the bar of the performance of the company and for our customers and patients.”
http://mrem.bernama.com/viewsm.php?idm=36647
Subscribe to:
Posts (Atom)